Grant: Engage Grants Program
McGill University
$25,000.00
A Leishmania display platform for expression of human antibodies and glycoproteins
EF 2017-18
Résumé
Immunoprecise Antibodies (IPA) is a Victoria, BC based company with expertise in development andproduction of murine and rabbit monoclonal antibodies (mAbs). To expand its competitive foot print in theantibody and recombinant protein production sector, IPA is exploring new strategies that will provide a morerapid turn around in the production of high quality therapeutic or research antibodies. In the production ofpolyclonal or monoclonal antibodies, one of the most time consuming steps is the immunization and boostingof host animals; which typically requires 50-60 days. To minimize this lag time IPA is interested in developinga new antibody production platform that circumvents the immunization step and will produced full length IgGantibodies that have the correct glycosylation patterns. Implementing this strategy will involve the developmentof an novel bicistronic vectors that will be used to create a surface display IgG library in the protozoanorganism Leishmania. Clones expressing the an IgG antibody that recognizes an antigen of interest can easilybe isolated using a biopanning approach. A major advantage for using Leishmania is that this organism hasglycosylation patterns that closely resemble thos observed on human and rabbit IgG antibodies. This projectwill provide that proof of principle data require for the ultimate creation of a human IgG surface display library.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
521175-2017
Name nom
Jardim, Armando
Department département
Parasitology, Institute of (Macdonald)
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
A Leishmania display platform for expression of human antibodies and glycoproteins
Keyword
NSERC
Application summary
Immunoprecise Antibodies (IPA) is a Victoria, BC based company with expertise in development andproduction of murine and rabbit monoclonal antibodies (mAbs). To expand its competitive foot print in theantibody and recombinant protein production sector, IPA is exploring new strategies that will provide a morerapid turn around in the production of high quality therapeutic or research antibodies. In the production ofpolyclonal or monoclonal antibodies, one of the most time consuming steps is the immunization and boostingof host animals; which typically requires 50-60 days. To minimize this lag time IPA is interested in developinga new antibody production platform that circumvents the immunization step and will produced full length IgGantibodies that have the correct glycosylation patterns. Implementing this strategy will involve the developmentof an novel bicistronic vectors that will be used to create a surface display IgG library in the protozoanorganism Leishmania. Clones expressing the an IgG antibody that recognizes an antigen of interest can easilybe isolated using a biopanning approach. A major advantage for using Leishmania is that this organism hasglycosylation patterns that closely resemble thos observed on human and rabbit IgG antibodies. This projectwill provide that proof of principle data require for the ultimate creation of a human IgG surface display library.